Informations générales (source: ClinicalTrials.gov)
Prevalence, Kinetic and Prognostic Value of XPO1 E571K Mutation Detection in Plasma Cell-free DNA From Patients Xith Classical Hodgkin Lymphoma (XPO1)
Interventional
N/A
Centre Henri Becquerel (Voir sur ClinicalTrials)
juin 2016
juin 2020
29 juin 2024
The purpose of this study is to determine if the XPO1 E571K mutation could be used as
molecular residual disease biomarker in classical Hodgkin's lymphoma. To determine the
interest of the mutation assessment by digital Polymerase Chain Reaction, sensitivity and
specificity after 2 courses of chemotherapy (C2) will be compared with the deltaSUVmax
determined by Positron Emission Tomography after C2 and at end of treatment.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Centre Henri Becquerel - 76000 - Rouen - France | Fabrice JARDIN, PUPH | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Age ≥18 years
- Pathologically confirmed, recent diagnosis of classical Hodgkin Lymphoma
- treatment planned with Adriamycin Bleamycin Vinblastine Dacarbazine (ABVD) or
Bleomycin Etoposide Adriamycin Cyclophosphamide Vincristine Procarbazine Prednisone
(BEACOPP) regimen (and radiotherapy if applicable)
- all stages (Ann Arbor I - IV)
- Written informed consent
- Patient affiliated or beneficiary of a benefit system
- untreated patient (no corticosteroids or chemotherapy)
- Age ≥18 years
- Pathologically confirmed, recent diagnosis of classical Hodgkin Lymphoma
- treatment planned with Adriamycin Bleamycin Vinblastine Dacarbazine (ABVD) or
Bleomycin Etoposide Adriamycin Cyclophosphamide Vincristine Procarbazine Prednisone
(BEACOPP) regimen (and radiotherapy if applicable)
- all stages (Ann Arbor I - IV)
- Written informed consent
- Patient affiliated or beneficiary of a benefit system
- untreated patient (no corticosteroids or chemotherapy)
- No informed consent
- Treatment by ABVD or BEACOPP not indicated
- Previously treated Hodgkin lymphoma (including corticosteroids)
- Patients who are pregnant or lactating
- Active Hepatitis B or Hepatitis C infection
- Known human immunodeficiency virus (HIV) infection - Patient with no social
protection
- Patient under tutorship or curatorship
- Patient not affiliated of beneficiary of a benefit system
- Medical contraindication to PET/CT